Vamorolone is a synthetic glucocorticoid used as an anti-inflammatory and immunosuppressant in the management of Duchenne muscular dystrophy (DMD). Vamorolone is a novel and fully synthetic glucocorticoid developed by Santhera Pharmaceuticals.
- Mechanism
- Curator reviewed · 2 references
Vamorolone is a synthetic corticosteroid that acts as an agonist at the glucocorticoid receptor to exert anti-inflammatory and immunosuppressive effects. It is also an antagonist of the mineralocorticoid receptor. The precise mechanism by which vamorolone exerts its therapeutic effects in patients with DMD is unclear.
- Primary indication
- Vamorolone is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients ≥2 years of age in the US and in patients ≥4 years of age in the EU.Curator reviewed · 2 structured indications
- Formula / weight
- C22H28O4 · 356.462 g/mol (avg)
- First approval
- Canada, 2025 · United States, 2023 · European Union, 2024
- Code names
- VBP15
- Brand names
Resolves to
ZYTXTXAMMDTYDQ-DGEXFFLYSA-NSMILESC[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@@]1(O)C(=O)COWhat you can answer from here — as of June 15, 2026
Which drugs share a target with Vamorolone, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account